Sugarloaf Wealth Management’s Apollo Endosurgery, Inc. APEN Stock Holding History

Sugarloaf Wealth Management’s Portfolio APEN Stock Details APEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-65	Closed	-$645	–	723
2023 Q1	$645	Hold	65	–	–	﹤0.01%	651
2022 Q4	$648	Hold	65	–	–	﹤0.01%	726
2022 Q3	$1K	Hold	65	–	–	﹤0.01%	823
2022 Q2	$0	Hold	65	–	–	﹤0.01%	849
2022 Q1	$0	Hold	65	–	–	﹤0.01%	778
2021 Q4	$1K	Hold	65	–	–	﹤0.01%	738
2021 Q3	$1K	Hold	65	–	–	﹤0.01%	752
2021 Q2	$1K	Hold	65	–	–	﹤0.01%	742
2021 Q1	$0	Hold	65	–	–	﹤0.01%	797
2020 Q4	$0	Hold	65	–	–	﹤0.01%	762
2020 Q3	$0	Hold	65	–	–	﹤0.01%	736
2020 Q2	$0	Hold	65	–	–	﹤0.01%	741
2020 Q1	$0	Hold	65	–	–	﹤0.01%	754
2019 Q4	$0	Buy	+65	New	+$188	﹤0.01%	715

Sugarloaf Wealth Management's APEN Position: Q2 2023 in Review

Sugarloaf Wealth Management sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 65 shares — an estimated $645 sold.

Sugarloaf Wealth Management first reported a position in APEN in Q4 2019 and held it in 14 quarters. The position peaked at $1K in Q3 2022. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

Sugarloaf Wealth Management reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
Sugarloaf Wealth Management sold 65 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $645.
Sugarloaf Wealth Management first reported a position in Apollo Endosurgery, Inc. in Q4 2019 and held it in 14 quarters.
Sugarloaf Wealth Management's Apollo Endosurgery, Inc. position peaked at $1K in Q3 2022.
0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Sugarloaf Wealth Management's 13F filing for Q2 2023, filed 13 Jul 2023.